Jounce Therapeutics is dedicated to transforming the treatment of cancer.Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce’s technology also looks to match and deliver the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as the knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable pipeline that makes a difference in the lives of cancer patients.
Recent Press Releases
08/02/18Jounce Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, Au...
06/02/18Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Pati...
View More Releases
NASDAQ GS JNCE (Common Stock)
$7.52 + 0.06 (0.80%)
Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.
08/16/18 4:00 p.m. ET
View More Events